Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to
stop cancer cells from dividing so they stop growing or die. Biological therapies such as
etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with
biological therapy may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects of giving arsenic trioxide
together with etanercept and to see how well it works in treating patients with
myelodysplastic syndromes.